{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:56:00Z","timestamp":1695275760632},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T00:00:00Z","timestamp":1379462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00393-013-1190-1","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T13:33:55Z","timestamp":1379338435000},"page":"784-790","source":"Crossref","is-referenced-by-count":3,"title":["Therapie der Psoriasisarthritis"],"prefix":"10.1007","volume":"72","author":[{"given":"E.","family":"M\u00e4rker-Hermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,18]]},"reference":[{"key":"1190_CR1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00393-008-0360-z","volume":"68","author":"M\u00e4rker-Hermann","year":"2009","unstructured":"M\u00e4rker-Hermann E, Behrens F (2009) Psoriasisarthritis. Zielkriterien der Behandlung. Z Rheumatol 68:16\u201322","journal-title":"Z Rheumatol"},{"key":"1190_CR2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","volume":"70","author":"Mumtaz","year":"2011","unstructured":"Mumtaz A, Gallagher P, Kirby B et al (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70:272\u2013277","journal-title":"Ann Rheum Dis"},{"key":"1190_CR3","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 39:2013\u20132020","journal-title":"Arthritis Rheum"},{"key":"1190_CR4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/rheumatology\/kes014","volume":"51","author":"Gutierrez","year":"2012","unstructured":"Gutierrez M, Di Geso L, Salaffi F, Bertolazzi C et al (2012) Development of a preliminary US power Doppler composite score for monitoring treatment in PsA. J Rheumatol 51:1261\u20131268","journal-title":"J Rheumatol"},{"key":"1190_CR5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939\u20131950","journal-title":"Arthritis Rheum"},{"key":"1190_CR6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","volume":"Res","author":"Behrens","year":"2013","unstructured":"Behrens F, Finkenwirth C, Pavelka K et al (2013) Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 65:464\u2013470","journal-title":"Arthritis Care"},{"key":"1190_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C et al (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapy. Ann Rheum Dis 71:4\u201312","journal-title":"Ann Rheum Dis"},{"key":"1190_CR8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","volume":"69","author":"Lie","year":"2010","unstructured":"Lie E, Heijde D van der, Uhlig T et al (2010) Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 69:671\u2013676","journal-title":"Ann Rheum Dis"},{"key":"1190_CR9","doi-asserted-by":"crossref","unstructured":"Kingsley GH, Kowalczyk A, Taylor H et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51:1368\u20131377","DOI":"10.1093\/rheumatology\/kes001"},{"key":"1190_CR10","first-page":"417","volume":"6","author":"Thorlund","year":"2012","unstructured":"Thorlund K, Druyts E, Avi\u00f1a-Zubieta JA, Mills EJ (2012) Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics 6:417\u2013427","journal-title":"Biologics"},{"key":"1190_CR11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","volume":"69","author":"Van","year":"2010","unstructured":"Van den Bosch F, Manger B, Goupille P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 69:394\u2013399","journal-title":"Ann Rheum Dis"},{"key":"1190_CR12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3899\/jrheum.110763","volume":"39","author":"Iervolino","year":"2012","unstructured":"Iervolino S, Di Minno MN, Peluso R et al (2012) Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-\u03b1 blockers. J Rheumatol 39:568\u2013573","journal-title":"J Rheumatol"},{"key":"1190_CR13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"Glintborg","year":"2011","unstructured":"Glintborg B, \u00d8stergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti \u2013 tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382\u2013390","journal-title":"Arthritis Rheum"},{"key":"1190_CR14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65:1213\u20131223","journal-title":"Arthritis Rheum"},{"key":"1190_CR15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675\u20131684","journal-title":"Lancet"},{"key":"1190_CR16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A et al (2009) Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633\u2013640","journal-title":"Lancet"},{"key":"1190_CR17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"McInnes","year":"2013","unstructured":"McInnes I, Kavanaugh A, Gottlieb AB et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789","journal-title":"Lancet"},{"key":"1190_CR18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","volume":"65","author":"Kary","year":"2006","unstructured":"Kary S, Worm M, Audring H et al (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65:405\u2013407","journal-title":"Ann Rheum Dis"},{"key":"1190_CR19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000339864","volume":"225","author":"Puig","year":"2012","unstructured":"Puig L, Morales-M\u00fanera CE, L\u00f3pez-Ferrer A, Geli C (2012) Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 225:14\u201317","journal-title":"Dermatology"},{"key":"1190_CR20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G et al (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a double-blind, randomized, placebo-controlled phase 2 trial. Arthritis Rheum 63:939\u2013948","journal-title":"Arthritis Rheum"},{"key":"1190_CR21","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-201897","volume":"71","author":"Jimenez-Boj","year":"2012","unstructured":"Jimenez-Boj E, Stamm TA, Sadlonova M et al (2012) Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 71:1868\u20131871","journal-title":"Ann Rheum Dis"},{"key":"1190_CR22","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3899\/jrheum.120201","volume":"39","author":"Wendling","year":"2012","unstructured":"Wendling D, Dougados M, Berenbaum F et al (2012) Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 39:2327\u20132331","journal-title":"J Rheumatol"},{"key":"1190_CR23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-010-1504-5","volume":"29","author":"Jung","year":"2010","unstructured":"Jung N, Hellmann M, Hoheisel R et al (2010) An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 29:1169\u20131173","journal-title":"Clin Rheumatol"},{"key":"1190_CR24","doi-asserted-by":"crossref","unstructured":"McInnes IB, Sieper J, Braun J et al (2013) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis (Epub ahead of print)","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"1190_CR25","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","volume":"64","author":"Schett","year":"2012","unstructured":"Schett G, Wollenhaupt J, Papp K et al (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64:3156\u20133167","journal-title":"Arthritis Rheum"},{"key":"1190_CR26","doi-asserted-by":"crossref","unstructured":"Kavanaugh A et al (2013) Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis. EULAR Annual European Congress of Rheumatology; 12\u201315 June 2013; Madrid, Spain. Abstract no. LB0001","DOI":"10.1136\/annrheumdis-2013-eular.526"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1190-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1190-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T04:10:05Z","timestamp":1563941405000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,18]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1190-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,18]]}}}